Literature DB >> 8892738

Atypical prolymphocytic variant of hairy-cell leukemia: case report and review of the literature.

C H Dunphy1, P J Petruska.   

Abstract

The prolymphocytic variant of hairy-cell leukemia (HCL-V) is relatively rare and differs from typical hairy-cell leukemia (HCL) both clinically and morphologically. Recognition of HCL-V is important due to therapeutic impact. We report on a case of HCL-V, atypical in its degree of marrow fibrosis, IgM/lambda monoclonality, expression of CD24, and the ultrastructural presence of ribosomal lamellar complexes. The patient was treated with splenectomy followed by pentostatin, and he achieved a partial response.

Entities:  

Mesh:

Year:  1996        PMID: 8892738     DOI: 10.1002/(SICI)1096-8652(199610)53:2<121::AID-AJH11>3.0.CO;2-I

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

1.  Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.

Authors:  Yi Wang; Tingyu Wang; Ying Yu; Qi Wang; Yuting Yan; Ru Li; Qi Sun; Wenjie Xiong; Rui Lyu; Zhen Yu; Wei Liu; Weiwei Sui; Wenyang Huang; Huijun Wang; Chengwen Li; Jun Wang; Dehui Zou; Gang An; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Ann Hematol       Date:  2022-04-18       Impact factor: 3.673

2.  Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.

Authors:  Haipeng Shao; Katherine R Calvo; Marlene Grönborg; Prashant R Tembhare; Robert J Kreitman; Maryalice Stetler-Stevenson; Constance M Yuan
Journal:  Leuk Res       Date:  2013-01-22       Impact factor: 3.156

3.  Immunophenotype and ultrastructure of B-cell lymphoproliferative disorder with cytoplasmic projection.

Authors:  Xinyue Liu; Xianshi Hu; Lihua Fan; Youbing Yuan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

Review 4.  Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant.

Authors:  Qiuying Liu; Nicholas Harris; Narendranath Epperla; Leslie A Andritsos
Journal:  Onco Targets Ther       Date:  2021-03-09       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.